227 related articles for article (PubMed ID: 1363289)
41. Lambert-Eaton myasthenic syndrome (LEMS): a rare autoimmune presynaptic disorder often associated with cancer.
Schoser B; Eymard B; Datt J; Mantegazza R
J Neurol; 2017 Sep; 264(9):1854-1863. PubMed ID: 28608304
[TBL] [Abstract][Full Text] [Related]
42. Decreased calcium currents in motor nerve terminals of mice with Lambert-Eaton myasthenic syndrome.
Smith DO; Conklin MW; Jensen PJ; Atchison WD
J Physiol; 1995 Aug; 487(1):115-23. PubMed ID: 7473242
[TBL] [Abstract][Full Text] [Related]
43. [Lambert-Eaton myasthenic syndrome, an immune pathology of neuromuscular junctions].
Honnorat J
Bull Acad Natl Med; 2014 Feb; 198(2):243-54; discussion 255. PubMed ID: 26263702
[TBL] [Abstract][Full Text] [Related]
44. Lambert-Eaton myasthenic syndrome: from clinical characteristics to therapeutic strategies.
Titulaer MJ; Lang B; Verschuuren JJ
Lancet Neurol; 2011 Dec; 10(12):1098-107. PubMed ID: 22094130
[TBL] [Abstract][Full Text] [Related]
45. Lambert-Eaton myasthenic syndrome.
Newsom-Davis J
Springer Semin Immunopathol; 1985; 8(1-2):129-40. PubMed ID: 2988146
[TBL] [Abstract][Full Text] [Related]
46. Lambert-Eaton myasthenic syndrome: mouse passive-transfer model illuminates disease pathology and facilitates testing therapeutic leads.
Meriney SD; Tarr TB; Ojala KS; Wu M; Li Y; Lacomis D; Garcia-Ocaña A; Liang M; Valdomir G; Wipf P
Ann N Y Acad Sci; 2018 Jan; 1412(1):73-81. PubMed ID: 29125190
[TBL] [Abstract][Full Text] [Related]
47. Interaction of synaptotagmin with voltage gated calcium channels: a role in Lambert-Eaton myasthenic syndrome?
David P; Martin-Moutot N; Leveque C; el Far O; Takahashi M; Seagar MJ
Neuromuscul Disord; 1993; 3(5-6):451-4. PubMed ID: 8186692
[TBL] [Abstract][Full Text] [Related]
48. Lambert-Eaton myasthenic syndrome: immunoglobulin G inhibition of Ca2+ flux in tumor cells correlates with disease severity.
Lang B; Vincent A; Murray NM; Newsom-Davis J
Ann Neurol; 1989 Mar; 25(3):265-71. PubMed ID: 2543262
[TBL] [Abstract][Full Text] [Related]
49. The effect of myasthenic syndrome antibody on presynaptic calcium channels in the mouse.
Lang B; Newsom-Davis J; Peers C; Prior C; Wray DW
J Physiol; 1987 Sep; 390():257-70. PubMed ID: 2450991
[TBL] [Abstract][Full Text] [Related]
50. Lambert-Eaton Myasthenic Syndrome.
Kesner VG; Oh SJ; Dimachkie MM; Barohn RJ
Neurol Clin; 2018 May; 36(2):379-394. PubMed ID: 29655456
[TBL] [Abstract][Full Text] [Related]
51. Action of Lambert-Eaton myasthenic syndrome IgG at mouse motor nerve terminals.
Prior C; Lang B; Wray D; Newsom-Davis J
Ann Neurol; 1985 Jun; 17(6):587-92. PubMed ID: 2992356
[TBL] [Abstract][Full Text] [Related]
52. [Lambert-Eaton myasthenic syndrome (LEMS)].
Suzuki S
Brain Nerve; 2010 Apr; 62(4):419-26. PubMed ID: 20420183
[TBL] [Abstract][Full Text] [Related]
53. SOX1 antibodies are markers of paraneoplastic Lambert-Eaton myasthenic syndrome.
Sabater L; Titulaer M; Saiz A; Verschuuren J; Güre AO; Graus F
Neurology; 2008 Mar; 70(12):924-8. PubMed ID: 18032743
[TBL] [Abstract][Full Text] [Related]
54. Simulations of active zone structure and function at mammalian NMJs predict that loss of calcium channels alone is not sufficient to replicate LEMS effects.
Ginebaugh SP; Badawi Y; Laghaei R; Mersky G; Wallace CJ; Tarr TB; Kaufhold C; Reddel S; Meriney SD
J Neurophysiol; 2023 May; 129(5):1259-1277. PubMed ID: 37073966
[TBL] [Abstract][Full Text] [Related]
55. Functional evaluation of inhibition of autonomic transmitter release by autoantibody from Lambert-Eaton myasthenic syndrome.
Houzen H; Hattori Y; Kanno M; Kikuchi S; Tashiro K; Motomura M; Nakao Y; Nakamura T
Ann Neurol; 1998 May; 43(5):677-80. PubMed ID: 9585366
[TBL] [Abstract][Full Text] [Related]
56. An autoimmune channelopathy associated with cancer: Lambert-Eaton myasthenic syndrome.
Takamori M
Intern Med; 1999 Feb; 38(2):86-96. PubMed ID: 10225662
[TBL] [Abstract][Full Text] [Related]
57. Lambert-Eaton myasthenic syndrome: clinical diagnosis, immune-mediated mechanisms, and update on therapies.
Sanders DB
Ann Neurol; 1995 May; 37 Suppl 1():S63-73. PubMed ID: 8968218
[TBL] [Abstract][Full Text] [Related]
58. Synaptotagmin can cause an immune-mediated model of Lambert-Eaton myasthenic syndrome in rats.
Takamori M; Hamada T; Komai K; Takahashi M; Yoshida A
Ann Neurol; 1994 Jan; 35(1):74-80. PubMed ID: 8285596
[TBL] [Abstract][Full Text] [Related]
59. Lambert-eaton myasthenic syndrome differential reactivity of tumor versus non-tumor patients to subunits of the voltage-gated calcium channel.
Pellkofer HL; Armbruster L; Krumbholz M; Titulaer MJ; Verschuuren JJ; Schumm F; Voltz R
J Neuroimmunol; 2008 Nov; 204(1-2):136-9. PubMed ID: 18809213
[TBL] [Abstract][Full Text] [Related]
60. Phoneutria nigriventer omega-Phonetoxin IIA: a new tool for anti-calcium channel autoantibody assays in Lambert-Eaton myasthenic syndrome.
Martin-Moutot N; Haro Ld; Santos RG; Mori Y; Seagar M
Neurobiol Dis; 2006 Apr; 22(1):57-63. PubMed ID: 16289869
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
